Articles

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution), commercialised as EvoTears in Europe, is the first prescription eye drop that targets tear evaporation.

At this year's ESCRS meeting, we visited the Oertli Instruments booth, where co-CEO and co-owner Thomas Bosshard highlighted the company's 3-platform approach.

At the 2023 European Society Of Cataract & Refractive Surgeons (ESCRS) meeting in Vienna, Krysten Williams, head of marketing and education at Heidelberg Engineering, spoke to our team about the newest imaging advancements in the clinic and the operating room.

Jorge Alio, MD, PhD, FEBOpthhal spoke with our team about his Binkhorst Medal lecture topic, the future of cataract and refractive surgery, while at the 2023 ESCRS meeting in Vienna, Austria.

Euan Thomson, the President of Ophthalmic Devices, Carl Zeiss Meditec spoke with our team about integrated workflow solutions and how they can benefit cataract procedures while at the 2023 ESCRS meeting in Vienna, Austria.

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

The company announced new data on outcomes for both open and narrow angle glaucoma patients.

Reviewing visual and anatomic outcomes in 2 clinical trials

Lenticule extraction poses a provocative question–and a complicated answer

According to the company, the deal expands its European footprint into Spain and Portugal.

One of AI’s most promising applications: new diagnostic algorithms

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin, PhD, and Carl Danzig, MD had to say!

Advancements from Carl Zeiss Medical AG in the cataract and cornea space include a new intraocular lens and therapeutic laser enhancements.

Maria H. Berrocal, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium in Marco Island, Florida.

The new platform incorporates the SILK procedure, allowing surgeons to perform refractive correction on patients with myopia.

The EUREQUO Annual Report celebrates 15 years and over 4 million surgical procedures in the registry.

According to the company, it is working with the FDA to address the agency’s issues.

Eva Kim, MD, spoke with our team to share insights from her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

OCT methods are invaluable in the assessment of patients with the condition

Commonly used immunosuppressants used in the short term to control an ocular inflammatory disease were not associated with increased risk of developing cancer later.

Surgeon discusses latest trends for treating cornea

This intellectual property protects Kiora's pipeline by covering several inflammatory-related therapeutic applications, including posterior non-infectious uveitis.

A multicentre study demonstrates comparable results to FS-LASIK

VG901 is a gene therapy for CNGA1-associated RP.

Researchers have identified markers that indicate the presence of Parkinson disease in patients an average of 7 years before the disease presents clinically.

The first-line treatment to avoid visual impairment for these cases is anti-vascular endothelial growth factor therapy (VEGF).